Serum Lipoprotein(a) Dynamics before/after Menopause and Long-term Effects of Hormone Replacement Therapy on Lipoprotein(a) Levels in Middle-aged and Older Japanese Women

Abstract

Aim: To assess lipoprotein(a) Lp(a) dynamics before and after menopause and to examine long-term changes during hormone replacement therapy (HRT) in middle-aged and older Japanese women. Methods: (1) Serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and Lp(a) concentrations of 526 patients were compared. The patients were divided into 3 groups on the basis of menopausal status (premenopause, perimenopause, postmenopause). (2) Serum markers of lipid metabolism were measured at baseline and at 6-month intervals in 161 postmenopausal women who continuously received HRT with conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) for 4 years. (3) Changes in serum concentrations of markers were compared among 120 women with hypercholesterolemia who were randomly assigned to receive HRT (CEE plus MPA, or transdermal estradiol plus MPA) or pravastatin. Results: (1) Lp(a) concentrations were significantly higher in the postmenopausal women than in the premenopausal or perimenopausal women. (2) The mean Lp(a) concentration after 6 months of HRT decreased by about 19%, and similar levels were maintained for 4 years (3). The mean Lp(a) concentration after 6 months of HRT decreased by 19.9% in the CEE plus MPA group, but did not change significantly in the transdermal estradiol plus MPA group or the pravastatin group. Conclusion: Our results suggest that HRT with CEE plus MPA is useful for the management of elevated serum Lp(a) concentrations in middle-aged and older women. However, follow-up studies are needed to determine whether this finding is related to the future prevention of coronary heart disease events.

Lipoprotein(a) - estrogen - menopause - hormone replacement therapy - pravastatin

References

• 1 Health Welfare Statistics Association . The movement of the population (in Japanese).  J Health Welfare Stat. 2004;  51 41-45
• 2 Berg K. A new type system in man: the Lp system.  Acta Pathol Microbiol Acand. 1963;  59 369-382
• 3 Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.  JAMA. 2000;  283 1845-1852
• 4 Jennifer LJ, Jose MO, Stefania L-F, Mary MS, Peter WFW, William PC, Ernst JS. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study.  Circulation. 1993;  87 1135-1141
• 5 Berg C, Mesch V, Boero L, Sayegh F, Parada M, Royer M, Muzzlo ML, Schreier L, Slseles N, Benencia H. Lipid and lipoprotein profile in menopausal transition. Effects of hormones, age and fat distribution.  Horm Metab Res. 2004;  36 215-220
• 6 Burschi F, Meschia M, Soma M, Perotti D, Paoletti R, Crosignani PG. Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy.  Obstet Gynecol. 1996;  88 950-954
• 7 Van der Mooren MJ, Mijatovic V, van Baal WM, Stehouwer CD. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease.  Maturitas. 1998;  30 27-36
• 8 Soma M, Fumagalli R, Paoletti R, Meschia M, Maini MC, Crosignani P, Granem K, Gaubatz J, Morrisett JD. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women.  Lancet. 1991;  337 612
• 9 Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein(a) concentration in postmenopausal women taking norethisterone.  Br Med J. 1991;  303 694
• 10 Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK, Wellington LP. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen.  Am J Obstet Gynecol. 1992;  166 1182-1190
• 11 Van der Mooren MJ, Demacker PNM, Thomas CMG, Borm GF, Rolland R. A 2-year study on the beneficial effects of 17β-estradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.  Eur J Obstet Gynecol Reprod Biol. 1993;  52 117-123
• 12 Marsh MS, Crook D, Whitcroft SIJ, Worthington M, Whitehead MI, Stevenson JC. Effects of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins.  Obstet Gynecol. 1994;  83 19-23
• 13 Taskinen MR, Puolakla J, Pyorala T, Luotola H, Biaorn M, Kaarianen J, Lahdenpera S, Ehnholm C. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.  Arterioscler Thromb Vasc Biol. 1996;  16 1215-1221
• 14 Mijatovic V, Kenemans P, Netelenbos JC, Peters-Muller ER, van Kamp GJ, Voetberg GA, van de Weijer PH. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) in healthy postmenopausal women.  J Clin Endocrinol Metab. 1997;  82 3543-3547
• 15 Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women.  Arterioscler Thromb Vasc Biol. 1997;  17 1822-1829
• 16 Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000.  Fertil and Steril. 2001;  75 898-915
• 17 Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women.  Obstet Gynecol. 1994;  84 987-995
• 18 Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effects of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.  Arch Intern Med. 1996;  156 1693-1700
• 19 Espeland M, Marcovina S, Miller V, Wood PD, Wasilauskasd C, Sherwin R, Schrott H, Bush TL. Effects of postmenopausal hormone therapy on lipoprotein(a) concentration.  Circulation. 1998;  97 979-986
• 20 Spencer C, Crook D, Ross D, Cooper A, Whitehead M, Stevenson J. A randomized comparison of the effects of oral versus transdermal 17β-estradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels.  Br J Obstet Gynaecol. 1999;  106 948-953
• 21 Farish E, Spowart K, Barnes JF, Fletcher C, Calder A, Brown A, Hart DM. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions.  Atherosclerosis. 1996;  126 77-84
• 22 Rozenberg S, Ylikorkala O, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.  Int J Fertil Menopausal Stud. 1997;  42 ((Suppl 2)) 376-387
• 23 Haenggi W, Lippuner K, Risen W, Jaeger P, Birkhauser MH. Long-term influence of different hormone replacement regimens on serum lipids and lipoprotein (a): a randomised study.  Br J Obstet Gynecol. 1997;  104 708-717
• 24 Schram JH, Boerrigter PJ, The TY. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone on lipid metabolism.  Maturitas. 1995;  22 121-130
• 25 McManus J, McEneny J, Thompson W, Young IS. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women.  Atherosclerosis. 1997;  135 73-81
• 26 Habiba M, Andrea A, Phipps B, al-Azzawi F. Thrombophilia and lipid profile in post-menopausal women using a new transdermal oestradiol patch.  Eur J Obstet Gynecol Reprod Biol. 1996;  66 165-168
• 27 Odmark I-S, Backstrom T, Haeger M, Jonsson B, Bixo M. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17β-estradiol/norethisterone acetate on lipids and lipoproteins.  Maturitas. 2004;  48 137-146
• 28 Bukowska H, Stanosz S, Zochowska E, Millo B, Sieja K, Chelstowski K, Naruszewicz M. Does the type of hormone replacement therapy affect lipoprotein(a), homocysteine, and C-reactive protein levels in postmenopausal women?.  Metabolism. 2005;  54 72-78
• 29 Ranta V, Oksanen H, Arrenbrecht S, Ylikorkala O. National differences in lipid response to postmenopausal hormone replacement.  Maturitas. 2002;  42 259-265
• 30 Vigna GB, Donega P, Zanca R, Barban A, Passaro A, Pansini F, Bonaccorsi G, Mollica G, Fellin R. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controled clinical trial.  Metabolism. 2002;  51 1463-1470
• 31 Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.  Gynecol Endocrinol. 2004;  18 244-257
• 32 Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogen/progestin, Replacement Study (HERS): design, methods, and baseline charcteristics.  Control Clin Trials. 1998;  19 314-335
• 33 Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the heart and estrogen/progestin replacement study. Lessons learned.  Circulation. 2002;  105 917-922
• 34 Writing Group for Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized trial.  JAMA. 2002;  288 321-333
• 35 Million Women Study Collaborators . Breast cancer and hormone replacement therapy in the Million Women Study.  Lancet. 2003;  362 419-427

1 Individual Contribution
Mariko Ushioda and Kazuya Makita contributed equally to the manuscript

Correspondence